Clinical Outcomes After Implantation of Polyurethane-Covered Cobalt-Chromium Stents : Insights from the Papyrus-Spain Registry
Copyright © 2020 Elsevier Inc. All rights reserved..
BACKGROUND/PURPOSE: The main indication of covered stents (CS) is coronary artery perforation (CAP), but, they have been increasingly used in other scenarios. Data on the long-term follow-up of CS is limited, and no studies have been conducted specifically using new-generation polyurethane-covered cobalt-chromium Papyrus CS.
PURPOSE: to evaluate the clinical outcomes after hospital discharge of Papyrus CS and to compare their outcome after implantation in CAP or coronary artery aneurysms (CAA).
METHODS/MATERIALS: We evaluated the baseline clinical characteristics, lesion subsets, procedural features and the outcomes after initial discharge of Papyrus CS implanted in 17 high-PCI-volume centers.
RESULTS: 127 Papyrus CS were implanted in 108 patients (68 ± 1 years; 82.8% male) admitted for stable coronary disease (32.3%), NSTEMI (42.4%) or STEMI (25.3%). The number of CS per patient was 1.2 ± 0.6 (diameter: 3.5 ± 1.7 mm; length: 18.5 ± 3.7 mm). Angiographic success rate was 96%. CS diameter was larger in CAA (CAP:3.04 ± 0.5 mm vs CAA:4.1 ± 2.7 mm; p = .022). Intracoronary imaging techniques were used more frequently in CAA (p < .0001). After a mean follow-up of 22 ± 16 months, the major cardiovascular adverse events (MACE) rate was 7.1% [cardiac death: 2%, Myocardial infarction: 5%, Target Lesion Revascularization: 5% and Stent Thrombosis (ST): 3%]. MACE rate was similar in CAP (7.7%) and CAA (7.1%) (p = .9). However, CAA showed a higher ST rate (CAP: 0% vs CA: 7.1%; p = .04).
CONCLUSION: After hospital discharge, clinical outcomes after Papyrus CS implantation are acceptable (considering the clinical scenario and compared with other treatment alternatives) with no significant differences in the MACE rate between those implanted in CAA or in CAP. However, CAA group showed a higher ST rate.
| Errataetall: |
CommentIn: Cardiovasc Revasc Med. 2021 Aug;29:29-31. - PMID 34420692 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Cardiovascular revascularization medicine : including molecular interventions - 29(2021) vom: 01. Aug., Seite 22-28 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jurado-Román, Alfonso [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0R0008Q3JB |
|---|
| Anmerkungen: |
Date Completed 22.10.2021 Date Revised 22.10.2021 published: Print-Electronic CommentIn: Cardiovasc Revasc Med. 2021 Aug;29:29-31. - PMID 34420692 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.carrev.2020.08.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314327053 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314327053 | ||
| 003 | DE-627 | ||
| 005 | 20231225152505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carrev.2020.08.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314327053 | ||
| 035 | |a (NLM)32859538 | ||
| 035 | |a (PII)S1553-8389(20)30486-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jurado-Román, Alfonso |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Outcomes After Implantation of Polyurethane-Covered Cobalt-Chromium Stents |b Insights from the Papyrus-Spain Registry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.10.2021 | ||
| 500 | |a Date Revised 22.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Cardiovasc Revasc Med. 2021 Aug;29:29-31. - PMID 34420692 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND/PURPOSE: The main indication of covered stents (CS) is coronary artery perforation (CAP), but, they have been increasingly used in other scenarios. Data on the long-term follow-up of CS is limited, and no studies have been conducted specifically using new-generation polyurethane-covered cobalt-chromium Papyrus CS | ||
| 520 | |a PURPOSE: to evaluate the clinical outcomes after hospital discharge of Papyrus CS and to compare their outcome after implantation in CAP or coronary artery aneurysms (CAA) | ||
| 520 | |a METHODS/MATERIALS: We evaluated the baseline clinical characteristics, lesion subsets, procedural features and the outcomes after initial discharge of Papyrus CS implanted in 17 high-PCI-volume centers | ||
| 520 | |a RESULTS: 127 Papyrus CS were implanted in 108 patients (68 ± 1 years; 82.8% male) admitted for stable coronary disease (32.3%), NSTEMI (42.4%) or STEMI (25.3%). The number of CS per patient was 1.2 ± 0.6 (diameter: 3.5 ± 1.7 mm; length: 18.5 ± 3.7 mm). Angiographic success rate was 96%. CS diameter was larger in CAA (CAP:3.04 ± 0.5 mm vs CAA:4.1 ± 2.7 mm; p = .022). Intracoronary imaging techniques were used more frequently in CAA (p < .0001). After a mean follow-up of 22 ± 16 months, the major cardiovascular adverse events (MACE) rate was 7.1% [cardiac death: 2%, Myocardial infarction: 5%, Target Lesion Revascularization: 5% and Stent Thrombosis (ST): 3%]. MACE rate was similar in CAP (7.7%) and CAA (7.1%) (p = .9). However, CAA showed a higher ST rate (CAP: 0% vs CA: 7.1%; p = .04) | ||
| 520 | |a CONCLUSION: After hospital discharge, clinical outcomes after Papyrus CS implantation are acceptable (considering the clinical scenario and compared with other treatment alternatives) with no significant differences in the MACE rate between those implanted in CAA or in CAP. However, CAA group showed a higher ST rate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Coronary artery aneurysms | |
| 650 | 4 | |a Coronary artery perforations | |
| 650 | 4 | |a Covered stents | |
| 650 | 7 | |a Polyurethanes |2 NLM | |
| 650 | 7 | |a Chromium |2 NLM | |
| 650 | 7 | |a 0R0008Q3JB |2 NLM | |
| 650 | 7 | |a Cobalt |2 NLM | |
| 650 | 7 | |a 3G0H8C9362 |2 NLM | |
| 700 | 1 | |a Rodríguez, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Amat, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Romani, Sebastián A |e verfasserin |4 aut | |
| 700 | 1 | |a García-Touchard, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz-González, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Benito-González, Tomás |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Cisnal, Agustín |e verfasserin |4 aut | |
| 700 | 1 | |a Córdoba-Soriano, Juan G |e verfasserin |4 aut | |
| 700 | 1 | |a Subinas, Asier |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Antolín, Rosana |e verfasserin |4 aut | |
| 700 | 1 | |a Bayón, Jeremías |e verfasserin |4 aut | |
| 700 | 1 | |a García-Tejada, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Salinas, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Lozano, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Bastante, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Núñez-Gil, Iván J |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Raúl |e verfasserin |4 aut | |
| 700 | 1 | |a López-Sendón, José Luis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular revascularization medicine : including molecular interventions |d 2005 |g 29(2021) vom: 01. Aug., Seite 22-28 |w (DE-627)NLM158711297 |x 1878-0938 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2021 |g day:01 |g month:08 |g pages:22-28 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.carrev.2020.08.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2021 |b 01 |c 08 |h 22-28 | ||